FirmaIQ
Org.nr 985 889 635 2020 → 2021 Year-over-year analysis

LYTIX BIOPHARMA ASA: årsregnskap 2021 vs 2020

Grew 287% on revenue, fresh owner capital

approved 2022-04-21; registry 2022-07-02; journal 2022 546743

Full company analysis · All year comparisons

Summary

What changed

Comparing Årsregnskap 2021 with 2020 for LYTIX BIOPHARMA ASA. Revenue 6.68m NOK → 25.83m NOK (+286.7%). Net result -42.09m NOK → -48.05m NOK. Equity 19.89m NOK → 189.62m NOK.

On the constructive side: revenue rose; equity strengthened; cash rose. Pressures included: operating result weakened; net result weakened.

Also worth watching: headcount (årsverk) changed. All figures are taken from the published annual accounts for LYTIX BIOPHARMA ASA.

At a glance

Scorecard

Revenue
6.68m NOK 25.83m NOK
+286.7%
Operating result
-42.37m NOK -48.02m NOK
-13.3%
Net result
-42.09m NOK -48.05m NOK
-14.2%
Equity
19.89m NOK 189.62m NOK
+853.4%
Cash
28.45m NOK 197.28m NOK
+593.4%
Total assets
32.62m NOK 202.96m NOK
+522.3%

What improved

  • ↑

    Revenue rose

    Operating income / revenue moved from 6.68m NOK to 25.83m NOK (+286.7% YoY). Calculated

  • ↑

    Equity strengthened

    Book equity 19.89m NOK → 189.62m NOK (equity ratio 61.0% → 93.4%). Calculated

  • ↑

    Cash rose

    Bank deposits 28.45m NOK → 197.28m NOK (+593.4% YoY). Calculated

  • ↑

    Owners injected capital

    Paid-in equity rose 19.89m NOK → 189.62m NOK (+169.74m NOK). Reported fact

What deteriorated

  • ↓

    Operating result weakened

    Operating result -42.37m NOK → -48.02m NOK (op. margin -634.5% → -185.9%). Calculated

  • ↓

    Net result weakened

    Net result -42.09m NOK → -48.05m NOK (net margin -630.2% → -186.0%). Calculated

Things to notice

  • ·

    Headcount (årsverk) changed

    Reported FTEs 7 → 8.3. Reported fact